With rates of preeclampsia skyrocketing, the U.S. FDA’s510(k) clearance of Roche Holding AG’s Elecsys test for preeclampsia offers some hope of reducing the number of women and infants who die or experience life-long consequences from the development of dangerously high blood pressure during late pregnancy and in the days immediately following delivery.
Heart disease remains the leading cause of death worldwide, and developing new therapeutic approaches constitutes an urgent healthcare priority. Almost one-third of patients surviving myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria.
Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Myocardial fibrosis is a key process for heart failure development that may lead to severe phenotypes, including cardiac arrest or sudden death. Vasorin (VASN) is a protein with high expression in the cardiovascular system and its upregulation had been found to protect smooth muscle cells from calcification.
Implanted patches of iPS-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
G protein-coupled receptor kinase 2 (GRK2) is involved in heart failure (HF) progression and its upregulation contributes to adverse cardiac remodeling and dysfunction. In mouse models of HF, inhibition of GRK2 has proven effective in improving cardiac function.
Researchers from The George Washington University and Northwestern University filed for protection of a bioresorbable, transparent, microelectrode array (MEA) technology that they believe offers unique advantages.
Fire1 Ltd. secured $120 million in financing to conduct a pivotal trial for its heart failure management system, Norm. The technology measures fluid in the inferior vena cava (IVC) and is expected to help the millions of people living with heart failure manage their condition and get their normal life back.
Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic that has demonstrated promising in vivo efficacy in multiple preclinical animal models.
